ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Sep 14, 2021 17:46 JST
Source:
Eisai
Eisai to Join The Global Environmental Initiative "RE100"
TOKYO, Sep 14, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has joined "RE100", the global environmental initiative that aims to shift the electricity used in business activities to 100% renewable electricity.
RE100 is an initiative committed to shifting the electricity used in business activities to 100% renewable energy with the aim of realizing a carbon-free society, and about 300 companies have joined worldwide. The Climate Group, an international environmental NGO, operates RE100 in partnership with CDP.
In May 2021, Eisai declared that it would achieve carbon neutrality in 2040 as a long-term goal for greenhouse gas (GHG) reduction. In addition, Eisai aims to increase the renewable energy usage rate of electricity throughout the Eisai Group to 100% by 2030 as its medium-term goal. With the accession to RE100, Eisai will accelerate its efforts to achieve the goals, promoting the use of solar power generation based on the PPA (Power Purchase Agreement) model and installing power generation equipment using natural energy in addition to the promotion of energy conservation and renewable energy utilization that has been carried out in Eisai.
Regarding Eisai's accession to RE100, Sam Kimmins, Head of RE100 at Climate Group said: "We are delighted that Eisai has joined RE100 the global initiative led by the Climate Group in partnership with CDP. By committing to 100% renewable electricity by 2030, Eisai is taking leadership in climate action. They join more than 50 Japanese RE100 companies who collectively, send a powerful message that renewable electricity makes good business sense."
Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides, and Eisai calls this philosophy the "human health care (hhc)" philosophy, in one word. To realize this hhc philosophy, Eisai will further strengthen its activities to ensure the sustainability of the global environment, which is the basis of its business activities.
For more detailed information about Eisai's environmental activities, please visit
https://www.eisai.com/sustainability/environment/index.html
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: Environment, ESG, BioTech
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Honda Develops New "Chemical Sorting" Technology to Separate Solid Contaminants from Waste Plastics Derived from End-of-life Automobiles
Sep 16, 2025 15:00 JST
NEC Publishes ESG Initiatives Supporting Sustainable Growth of Companies and Society in "ESG Databook 2025"
Sep 16, 2025 14:00 JST
JSR Corporation/Inpria Corporation and Lam Research Enter Cross Licensing and Collaboration Agreement to Advance Semiconductor Manufacturing
Sep 16, 2025 09:00 JST
Toyota Launches Next-Generation New Mobility e-Palette
Sep 15, 2025 15:33 JST
The University of Osaka D3 Center Commences Operation of New Computing and Data Infrastructure Built by NEC
Sep 12, 2025 15:08 JST
GR Yaris "Aero performance package" Set for Japan Launch
Sep 12, 2025 14:40 JST
Mitsubishi Heavy Industries Achieves Target Performance at Pilot Plant for Bioethanol Membrane Dehydration Systems
Sep 12, 2025 14:19 JST
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
Sep 12, 2025 13:20 JST
TANAKA PRECIOUS METAL TECHNOLOGIES Succeeds in Developing High-Performance Palladium Alloy Hydrogen Permeable Membrane Operable in the Low-Temperature Range of 300 degrees C
Sep 12, 2025 11:00 JST
CO2NNEX(R) Digital Platform for Transfer and Management of e-Methane Clean Gas Certificates to Be Utilized in Nagaoka Methanation Demonstration
Sep 11, 2025 20:37 JST
Hitachi accelerates growth with major U.S. investments in advanced manufacturing, electrification and workforce development
Sep 11, 2025 18:35 JST
GlobalLogic and Ericsson Deploy Private 5G Network at Hitachi Rail's State-of the-Art Digital Factory
Sep 11, 2025 17:24 JST
GlobalLogic and Flexware Innovation Announce Major Deployment of LIFT at Hitachi Rail's State-of-the-Art Train Manufacturing Facility
Sep 11, 2025 16:46 JST
JCB Unveils New Brand Message in Vietnam: "Japan Cung Ban"
Sep 11, 2025 13:00 JST
Kawasaki City becomes first dekokatsu subsidy municipality for promoting decarbonization lifestyle promotion project
Sep 11, 2025 10:35 JST
TGR Plans to Reproduce Engine Parts for Corolla Levin / Sprinter Trueno (AE86)
Sep 10, 2025 18:11 JST
TANAKA Acts as Category Sponsor for the LIGA.i Blind Soccer Top League 2025
Sep 10, 2025 03:00 JST
Toyota Submits Fourth Progress Report on Measures to Prevent Recurrence
Sep 09, 2025 19:26 JST
The 46th Honda Prize 2025 Awarded to Dr. Kenichi IGA
Sep 09, 2025 19:06 JST
Lexus world premieres the new IS
Sep 09, 2025 18:26 JST
More Latest Release >>
Related Release
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
9/12/2025 1:20:00 PM JST
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
9/8/2025 5:49:00 PM JST
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
9/4/2025 10:56:00 AM JST
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
9/3/2025 11:32:00 AM JST
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
9/1/2025 1:44:00 PM JST
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
8/29/2025 6:17:00 PM JST
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
8/25/2025 7:30:00 PM JST
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
8/18/2025 9:11:00 AM JST
Revenue of LEQEMBI(R) (Preliminary Basis)
7/31/2025 6:27:00 PM JST
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
7/31/2025 9:30:00 AM JST
More Press release >>